The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy ...

Enzalutamide/leuprolide reduced metastasis or death versus leuprolide alone (HR 0.42) and improved overall survival (HR 0.597); enzalutamide monotherapy also improved ...

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and ...

The ANDROMEDA trial compares alpha-emitting 225Ac-PSMA-617 and beta-emitting 177Lu-PSMA-617 with SBRT for recurrent oligometastatic prostate cancer. The trial builds on the LUNAR trial, which showed ...

Enolen's fast track designation by the FDA highlights its potential to address unmet needs in early-stage prostate cancer treatment. The implant technology aims to deliver high local drug ...

One of the most notable changes is a new thematic structure within urologic oncology. In this video, Bruno Nahar, MD, an associate professor of urologic oncology and the Eric and Elizabeth Feder ...

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...

The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...

Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...